
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is facing some short-term challenges due to slower sales of its WATCHMAN product, but its broad and innovative product portfolio as well as strong revenue from other segments should drive sustainable growth in the long run. The company's plans for expansion and cost reduction should also support earnings growth. Some risks include lower-than-expected sales and loss of market share to competitors. However, we maintain a positive outlook for the company's stock with a Buy rating based on its strong financial metrics and potential for future growth.
Bears say
Boston Scientific is experiencing numerous headwinds, forecasting WATCHMAN sales is difficult due to recent clinical trials, reimbursement changes, and physician concerns. The company's reported Q1 revenue beat was due to management's conservative assumptions, and overall organic growth of ~6% in 2027 and 2028 is expected, warranting a 16.0x P/E multiple. Despite this, recent product weakness and lowered guidance have resulted in a negative near-term sentiment for the company.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares